Cancer treatment has changed significantly as researchers have learned more about the molecular differences between tumors. Patients with the same cancer diagnosis may have different genetic alterations, treatment responses, and disease progression patterns. Precision medicine helps clinicians account for these differences when selecting appropriate treatment strategies.

Rather than relying solely on the organ where cancer begins, precision oncology may consider molecular biomarkers, tumor characteristics, disease stage, previous treatment, and a patient's overall health. These details can help determine whether a targeted medicine, immunotherapy, or another approach is appropriate.

For readers interested in evidence-based cancer education, ONC Brothers offers oncology discussions covering clinical developments and treatment approaches.

What Is Precision Medicine?

Precision medicine is an approach to healthcare that uses relevant biological, clinical, and sometimes genetic information to guide decisions for an individual patient. In oncology, this often involves studying a tumor's molecular features to identify characteristics that may influence treatment.

Traditional cancer classifications remain important. The location, size, stage, pathology, and spread of a tumor still guide many treatment decisions. Molecular information adds another layer of detail rather than replacing these established assessments.

Precision medicine can help identify patients who may benefit from specific treatments, avoid certain ineffective therapies when reliable evidence supports doing so, and improve understanding of why a cancer responds or becomes resistant.

However, personalized care does not mean that every patient receives a completely unique medicine. Many treatment recommendations are based on evidence from groups of patients with similar clinical and molecular characteristics.

Understanding Biomarker Testing

A biomarker is a measurable biological feature that may provide information about a disease or its response to treatment. In cancer care, biomarkers can include gene mutations, protein expression, chromosome changes, and other molecular characteristics.

Biomarker testing may help clinicians identify treatment options for certain cancers. For example, specific alterations in the EGFR gene can influence treatment decisions in some non-small cell lung cancers. HER2 status helps guide therapy for selected breast and other cancers. Microsatellite instability and mismatch repair status can also influence immunotherapy decisions in appropriate settings.

Different tests answer different questions. Immunohistochemistry measures proteins in tissue, while molecular tests may identify genetic alterations. Next-generation sequencing can assess multiple genomic regions in a single test, depending on the panel used.

The choice of test depends on the cancer type, disease stage, available tissue, clinical question, and applicable guidelines. Not all biomarkers are relevant to every cancer, and not every result identifies an effective treatment.

How Molecular Profiling Influences Treatment

Molecular profiling involves analyzing tumor material to identify potentially meaningful biological changes. When a result matches a treatment supported by clinical evidence and approved or recommended for the relevant situation, it may help guide therapy selection.

This approach is especially important in several advanced cancers, where identifying an actionable alteration may open additional treatment options. In some cases, testing can also help identify eligibility for a clinical trial.

Molecular profiling has limitations. A tumor sample may not contain enough material for testing, and some cancers evolve over time. In addition, a detected alteration may be uncertain in significance or may not have an established treatment associated with it.

Clinicians must interpret molecular results alongside pathology reports, imaging, symptoms, previous treatment, and the patient's preferences. Testing should answer a meaningful clinical question rather than be ordered without considering whether the results could influence care.

Targeted Therapy in Modern Oncology

Targeted therapies act on specific molecules or pathways involved in cancer growth, survival, or spread. Some block abnormal signaling proteins, while others interfere with processes that cancer cells depend on.

When a tumor has the appropriate target, a targeted medicine may provide meaningful benefit. In selected cancers, these treatments can produce substantial responses and may offer alternatives to other systemic therapies.

Nevertheless, targeted therapy is not universally effective. Tumors can contain several different cell populations, and resistance can emerge when some cancer cells survive treatment. Resistance may develop through new genetic changes, alternative signaling pathways, or other biological mechanisms.

Researchers are investigating combination therapies, new generations of targeted medicines, and improved molecular monitoring to address these challenges. The most suitable approach depends on the cancer's characteristics and the available evidence.

Precision Immunotherapy

Immunotherapy aims to help the immune system recognize and attack cancer. Some immunotherapies work by blocking immune checkpoints that tumors exploit to suppress immune activity.

Biomarkers can help estimate whether a patient is likely to benefit from certain immunotherapies. Depending on the cancer and treatment, these may include PD-L1 expression, mismatch repair deficiency, microsatellite instability, or tumor mutational burden.

These markers are not perfect predictors. A positive result does not guarantee a response, and some patients with negative results may still benefit in specific circumstances. Interpretation depends on the cancer type, assay, treatment, and applicable clinical guidance.

Immune-related adverse events also require careful monitoring. Inflammation can affect healthy organs, sometimes after treatment has ended. Patients should report new or worsening symptoms to their oncology team promptly.

Challenges and Limitations of Personalized Cancer Care

Despite its potential, precision medicine faces several challenges. Testing may be expensive or unavailable in some healthcare settings, and access to molecular pathology services varies. Tissue samples may be inadequate, and results can take time to obtain.

Another challenge is interpreting uncertain findings. Not every genetic alteration is responsible for cancer growth, and not every detected change has a proven treatment. Researchers must distinguish clinically actionable biomarkers from findings that remain investigational.

Genetic information also raises privacy and consent considerations. Patients should understand what a test examines, what its results may reveal, and whether testing could identify inherited risks that have implications for relatives.

Equitable access is important. The benefits of scientific progress are limited if patients cannot obtain appropriate testing, specialist interpretation, or indicated treatment.

The Importance of Clinical Evidence

Precision oncology depends on high-quality research. Clinical trials evaluate whether treatments improve outcomes, which patient groups benefit, and what side effects may occur. Guidelines then help translate the evidence into practical recommendations.

Clinicians also consider whether the evidence applies to a particular patient. Trial participants may differ from the patient being treated in age, other medical conditions, disease stage, or previous therapies. These differences can influence how study results should be interpreted.

Educational resources such as ONC Brothers' HER2-positive lung cancer discussion illustrate how molecular testing and treatment evidence can inform specialist conversations.

For broader perspectives on changing treatment approaches, oncology research and clinical updates can help readers explore discussions about emerging evidence and clinical practice.

The Future of Precision Oncology

Research continues to investigate circulating tumor DNA, improved genomic testing, artificial intelligence, and treatments designed for specific molecular characteristics. Liquid biopsy may support selected clinical decisions by detecting tumor-derived DNA in blood, although sensitivity varies and tissue testing may still be necessary.

Researchers are also exploring ways to monitor minimal residual disease after treatment. In some cancers, these tests may provide useful prognostic information, but their role in directing treatment decisions is still being established in many settings.

The future of precision oncology will depend on rigorous clinical trials, accurate diagnostics, affordable access, and careful evaluation of long-term outcomes.

Conclusion

Precision medicine has expanded the ability of oncology teams to select treatments according to tumor biology and individual clinical circumstances. Biomarker testing, molecular profiling, targeted therapy, and immunotherapy can provide important options for appropriately selected patients.

These methods work best when combined with established diagnostic practices, clinical expertise, shared decision-making, and reliable evidence. Personalized cancer care is an evolving field, and its benefits must always be considered alongside uncertainty, potential toxicity, and patient preferences.

Medical disclaimer: This article is intended for education and does not provide individual medical advice. Patients should consult their oncology team before making decisions about testing or treatment.